Idorsia Pharmaceuticals Ltd: Idorsia announces the results of MODIFY, a Phase 3 study of lucerastat in Fabry disease

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - October 11, 2021Idorsia Ltd (SIX: IDIA) today announced that MODIFY, the Phase 3 study to investigate the effect of lucerastat, as

Related Keywords

Allschwil ,Switzerland General ,Switzerland ,Swiss ,Andrewc Weiss ,Guy Braunstein ,Jean Paul Clozel ,Developmentat Idorsia ,Idorsia Ltd ,Head Of Investor Relations Corporate Communications ,Idorsia Pharmaceuticals Ltd ,Swiss Exchange ,Global Clinical Developmentat Idorsia ,Paul Clozel ,Chief Executive Officer ,Vice President ,Investor Relations ,Pharmaceuticals Ltd ,Idorsia ,Pharmaceuticals ,Nnounces ,Results ,Codify ,Hase ,Study ,Ucerastat ,Dabry ,Disease ,